Current and Emerging Inhaled Antibiotics for Chronic Pulmonary <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> Infections in Cystic Fibrosis
Characterized by impaired mucus transport and subsequent enhanced colonization of bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic fibrosis (CF). <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) and <i>Staphylococcus aureus&...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2023-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Characterized by impaired mucus transport and subsequent enhanced colonization of bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic fibrosis (CF). <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) and <i>Staphylococcus aureus</i> (<i>S. aureus</i>) are the two most common types of bacteria detected in CF lungs, which undergo multiple adaptational mechanisms such as biofilm formation resulting in chronic pulmonary infections. With the advantages of greater airway concentration and minimized systemic toxicity, inhaled antibiotics are introduced to treat chronic pulmonary infection in CF. Inhaled tobramycin, aztreonam, levofloxacin, and colistin are the four most common discussed inhaled antibiotics targeting <i>P. aeruginosa</i>. Additionally, inhaled liposomal amikacin and murepavadin are also in development. This review will discuss the virulence factors and adaptational mechanisms of <i>P. aeruginosa</i> and <i>S. aureus</i> in CF. The mechanism of action, efficacy and safety, current status, and indications of corresponding inhaled antibiotics will be summarized. Combination therapy and the strategies to select an optimal inhaled antibiotic protocol will also be discussed. |
|---|---|
| Item Description: | 10.3390/antibiotics12030484 2079-6382 |